Non-Current Assets
Investments - Amortized Cost Basis
Regeneron Pharmaceuticals Investments - Amortized Cost Basis increased by 71.1% to $571.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 80.4%, from $316.80M to $571.60M. Over 5 years (FY 2020 to FY 2025), Investments - Amortized Cost Basis shows an upward trend with a 41.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2017
Last reportedQ1 2026Apr 29, 2026
Metric ID:
investments_amortized_costHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $40.00M | $40.00M | $40.00M | $46.70M | $47.30M | $48.30M | $48.30M | $48.30M | $78.30M | $60.80M | $74.30M | $73.70M | $196.80M | $159.80M | $159.80M | $316.80M | $316.80M | $316.80M | $334.00M | $571.60M |
| QoQ Change | — | +0.0% | +0.0% | +16.8% | +1.3% | +2.1% | +0.0% | +0.0% | +62.1% | -22.3% | +22.2% | -0.8% | +167.0% | -18.8% | +0.0% | +98.2% | +0.0% | +0.0% | +5.4% | +71.1% |
| YoY Change | — | — | — | — | +18.3% | +20.8% | +20.8% | +3.4% | +65.5% | +25.9% | +53.8% | +52.6% | +151.3% | +162.8% | +115.1% | +329.9% | +61.0% | +98.2% | +109.0% | +80.4% |
Range$40.00M – $571.60M
CAGR+75.1%
Avg YoY Growth+85.5%
Median YoY Growth+63.3%
Current Streak6 quarters growth
Investments - Amortized Cost Basis at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's investments - amortized cost basis?
- Regeneron Pharmaceuticals (REGN) reported investments - amortized cost basis of $571.60M in Q1 2026.
- How has Regeneron Pharmaceuticals's investments - amortized cost basis changed year-over-year?
- Regeneron Pharmaceuticals's investments - amortized cost basis increased by 80.4% year-over-year, from $316.80M to $571.60M.
- What is the long-term trend for Regeneron Pharmaceuticals's investments - amortized cost basis?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's investments - amortized cost basis has grown at a 41.3% compound annual growth rate (CAGR), from $59.20M to $334.00M.